Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. (Q30394541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

0 references

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Laurent Arthur Decosterd

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Pascal Meylan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Anton Ivanyuk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Manel Aouri

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Thierry Buclin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

1 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

741-765

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20923248%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000

15 February 2020

exact match

0 references

cites work

Reducing the burden of influenza-associated complications with antiviral therapy

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

The metabolism and transplacental transfer of oseltamivir in the ex vivo human model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11534730-000000000-00000

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

21 January 2018

1 reference

12 December 2020

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

1 reference

12 December 2020

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance

1 reference

12 December 2020

H1N1 2009 influenza virus infection during pregnancy in the USA.

1 reference

12 December 2020

Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

1 reference

12 December 2020

Possible origin of current influenza A H1N1 viruses.

1 reference

12 December 2020

A history of influenza

1 reference

12 December 2020

Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support

1 reference

12 December 2020

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

1 reference

12 December 2020

Comments on "Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel"

1 reference

12 December 2020

Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants

1 reference

12 December 2020

P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.

1 reference

12 December 2020

High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde

1 reference

12 December 2020

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

1 reference

12 December 2020

Neuraminidase inhibitors: zanamivir and oseltamivir

1 reference

12 December 2020

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children

1 reference

12 December 2020

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

1 reference

12 December 2020

H1N1 pneumonitis treated with intravenous zanamivir

1 reference

12 December 2020

WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

1 reference

12 December 2020

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe

1 reference

12 December 2020

Principles and clinical application of assessing alterations in renal elimination pathways.

1 reference

12 December 2020

Influenza virus resistance to oseltamivir: what are the implications?

1 reference

12 December 2020

Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1.

1 reference

12 December 2020

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

1 reference

12 December 2020

Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor

1 reference

12 December 2020

Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence.

1 reference

12 December 2020

The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

12 December 2020

H1N1 vaccine for prevention of pandemic influenza

1 reference

12 December 2020

Oseltamivir resistance during treatment of influenza A (H5N1) infection

1 reference

12 December 2020

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

1 reference

12 December 2020

Safety and pharmacokinetics of oseltamivir at standard and high dosages

1 reference

12 December 2020

Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

1 reference

12 December 2020

In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite

1 reference

12 December 2020

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

1 reference

12 December 2020

Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

1 reference

12 December 2020

A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir.

1 reference

12 December 2020

Genetic variation in drug transporters in ethnic populations

1 reference

12 December 2020

Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

1 reference

12 December 2020

A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.

1 reference

12 December 2020

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

1 reference

12 December 2020

Oseltamivir for treatment and prophylaxis of influenza infection

1 reference

12 December 2020

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

1 reference

12 December 2020

A/H1N1 pandemic. Oseltamivir's adverse events

1 reference

12 December 2020

Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?

1 reference

12 December 2020

Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic a

1 reference

12 December 2020

WHO declares that H1N1 pandemic is officially over

1 reference

12 December 2020

The generation of influenza outbreaks by a network of host immune responses against a limited set of antigenic types

1 reference

12 December 2020

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.

1 reference

12 December 2020

The M2 proton channels of influenza A and B viruses

1 reference

12 December 2020

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

1 reference

12 December 2020

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

1 reference

12 December 2020

A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.

1 reference

12 December 2020

Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin

1 reference

12 December 2020

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

12 December 2020

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

1 reference

12 December 2020

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system

1 reference

12 December 2020

Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza

1 reference

12 December 2020

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

1 reference

12 December 2020

Avian influenza (H5N1): implications for intensive care.

1 reference

12 December 2020

Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan

1 reference

12 December 2020

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States

1 reference

12 December 2020

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.

1 reference

12 December 2020

Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.

1 reference

12 December 2020

World Health Organization declares A (H1N1) influenza pandemic

1 reference

12 December 2020

Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus

1 reference

12 December 2020

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

1 reference

12 December 2020

Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.

1 reference

12 December 2020

Tamiflu side effects come under scrutiny

1 reference

12 December 2020

The evolution of influenza resistance and treatment.

1 reference

12 December 2020

Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons

1 reference

12 December 2020

Neuraminidase inhibitors for influenza

1 reference

12 December 2020

Health outcomes among patients receiving oseltamivir.

1 reference

12 December 2020

Oseltamivir and breastfeeding

1 reference

12 December 2020

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

1 reference

12 December 2020

Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women

1 reference

12 December 2020

Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature.

1 reference

12 December 2020

Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus

1 reference

12 December 2020

Importance of collection tube during clinical studies of oseltamivir

1 reference

12 December 2020

Tamiflu and neuropsychiatric disturbance in adolescents

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

1 reference

12 December 2020

An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.

1 reference

12 December 2020

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

1 reference

12 December 2020

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants

1 reference

12 December 2020

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

12 December 2020

Why don't we have all the evidence on oseltamivir?

1 reference

12 December 2020

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

1 reference

12 December 2020

Potential risks associated with the proposed widespread use of Tamiflu.

1 reference

12 December 2020

Safety and pharmacology of oseltamivir in clinical use.

1 reference

12 December 2020

Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases

1 reference

12 December 2020

Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

1 reference

12 December 2020

BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence

1 reference

12 December 2020

Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.

1 reference

12 December 2020

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

1 reference

12 December 2020

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

1 reference

12 December 2020

Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine

1 reference

12 December 2020

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin

1 reference

12 December 2020

Side effects of Tamiflu: clues from an Asian single nucleotide polymorphism.

1 reference

12 December 2020

Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases

1 reference

12 December 2020

Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses

1 reference

12 December 2020

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

12 December 2020

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

1 reference

12 December 2020

1 reference

12 December 2020

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection

1 reference

12 December 2020

Oseltamivir (tamiflu) is a substrate of peptide transporter 1.

1 reference

12 December 2020

Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes

1 reference

12 December 2020

Critical care services and 2009 H1N1 influenza in Australia and New Zealand.

1 reference

12 December 2020

Oseltamivir dosing for influenza infection in premature neonates

1 reference

12 December 2020

An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration

1 reference

12 December 2020

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis

1 reference

12 December 2020

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

1 reference

12 December 2020

Population pharmacokinetics of oseltamivir when coadministered with probenecid

1 reference

12 December 2020

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

1 reference

12 December 2020

Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection

1 reference

12 December 2020

Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.

1 reference

12 December 2020

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

1 reference

12 December 2020

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

1 reference

12 December 2020

Risk of confusion in dosing Tamiflu oral suspension in children

1 reference

12 December 2020

A measure of resistance: detecting Tamiflu metabolite in sewage discharge and river water

1 reference

12 December 2020

The environmental fate of the antiviral drug oseltamivir carboxylate in different waters.

1 reference

12 December 2020

Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.

1 reference

12 December 2020

Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure

1 reference

12 December 2020

The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza

1 reference

12 December 2020

Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir

1 reference

12 December 2020

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

1 reference

12 December 2020

Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

1 reference

12 December 2020

Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method

1 reference

12 December 2020

Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey.

1 reference

12 December 2020

Safety of oseltamivir in pregnancy: a review of preclinical and clinical data

1 reference

12 December 2020

Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir

1 reference

12 December 2020

Oseltamivir in human avian influenza infection.

1 reference

12 December 2020

1 reference

12 December 2020

Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River

1 reference

12 December 2020

Influenza virus resistance to antiviral agents: a plea for rational use.

1 reference

12 December 2020

Rational design of potent sialidase-based inhibitors of influenza virus replication

1 reference

12 December 2020

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

1 reference

12 December 2020

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

1 reference

12 December 2020

Pharmacokinetics of oseltamivir in young and very elderly subjects.

1 reference

12 December 2020

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

1 reference

12 December 2020

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers

1 reference

12 December 2020

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

1 reference

12 December 2020

Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites.

1 reference

12 December 2020

Pharmacokinetics of high-dose oseltamivir in healthy volunteers

1 reference

12 December 2020

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).

1 reference

12 December 2020

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

1 reference

12 December 2020

Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry

1 reference

12 December 2020

Oseltamivir dosing in children undergoing hemodialysis

1 reference

12 December 2020

Zanamivir: from drug design to the clinic

1 reference

12 December 2020

Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

1 reference

12 December 2020

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

1 reference

12 December 2020

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

1 reference

12 December 2020

Mechanisms of renal anionic drug transport

1 reference

12 December 2020

Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009

1 reference

12 December 2020

Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.

1 reference

12 December 2020

Oseltamivir: cutaneous and neurological adverse effects in children

1 reference

12 December 2020

Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein.

1 reference

12 December 2020

What is the optimal therapy for patients with H5N1 influenza?

1 reference

12 December 2020

The war against influenza: discovery and development of sialidase inhibitors

1 reference

12 December 2020

Experience with oseltamivir for infants younger than 1 year old in Japan

1 reference

12 December 2020

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

12 December 2020

Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience

1 reference

12 December 2020